11/13 Taiwan Life Sciences Biweekly Newsletter
2023-11-14
| Taiwan Life Sciences Biweekly |
| iGEM winning teams urge greater support for synthetic biology sector 10 November, 2023 Several people involved in Taiwan's synthetic biology sector have called for more support for the sector after teams from Taiwan performed well at the International Genetically Engineered Machine (iGEM) competition, which took place in Paris Nov. 2-5. Participating teams from Taiwan won six gold medals, four silver medals and several other prizes at the competition, which focuses on synthetic biology development. More... |
| H2U Secures Strategic Investment from InnoTherapy as Recognition from Seoul Clinical Laboratories (SCL) Press release 10 November, 2023 H2U, Taiwan's premier digital health brand, proudly announced another successful round of funding this year after receiving recognition from South Korean medical laboratory powerhouse SCL (Seoul Clinical Laboratories). The partnership is solidified through a strategic investment from InnoTherapy Inc. (KOSDAQ: 246960), an affiliated company under the SCL Group. More... |
| Taiwan's first brain bank opens in Taipei 6 November, 2023 The nation's first brain bank opened in Taipei yesterday, with Premier Chen Chien-jen expressing his hopes that it would also make Taiwan a bellwether in neuroscience in Asia. National Taiwan University's (NTU) College of Medicine yesterday hosted a plaque unveiling ceremony for the Taiwan Brain Bank, which was attended by Chen, National Health Research Institutes president Sytwu Huey-kang, NTU vice president Chang Shan-chwen, Minister of Health and Welfare Hsueh Jui-yuan and Taiwan Brain Bank Association chairman Hsieh Sung-tsang. More... |
| Diamond Biofund Announces Collaboration for Cross-Border Biomedical Investment Projects 6 November, 2023 Diamond Biofund (TW: 6901) and Japan's DCI Partners jointly announced that they have established cross-border investment cooperation to facilitate flagship investments in the field of biotechnology and medical sciences. They have initially focused on areas such as cell therapy, nucleic acid drugs, and regenerative medicine. More... (in Chinese) |
| Cancer Resource Center unveiled at Taipei Veterans General Hospital 3 November, 2023 Following the inclusion of more cancer drugs in Taiwan's National Health Insurance (NHI), hospitals are also investing in resources for cancer patients. Taipei Veterans General Hospital (TVGH) unveiled a "Cancer Resource Centre" on 2 November to provide advice and a dedicated space for patients. Taipei Veterans General Hospital Superintendent Wei-Ming Chen said the Heavy Ion Therapy Centre, which opened in May this year, is expected to serve more than 100 patients by the end of this year. More... |
| FullHope Biomedical Partners with Chenglin to Enter China Cell Therapy Market 2 November, 2023 On October 27, FullHope Biomedical and Chenglin International signed an intention agreement for cell technology licensing cooperation with the goal of jointly developing the cell therapy market in China. Through collaboration with major medical centers in Taiwan, FullHope Biomedical has gradually validated the clinical efficacy of its research and development projects related to precision diagnosis, integrated treatments (including immunotherapy and regenerative medicine), utilizing feedback from clinical physicians. In addition to the development of cancer immunotherapy, FullHope Biomedical has developed a unique immunofunction analysis platform and circulating tumor cell analysis technology, enabling precise diagnosis and customized immunotherapy. This approach helps more patients find the most suitable treatment plans based on their individual needs. More... (in Chinese) |
| Kim Forest Collaborates with International Giant Waters to Expand Human PFASs Testing Business Press release 2 November, 2023 Kim Forest (TW: 6645), a high-end genetic testing instrument and service manufacturer, announced a collaboration with the leading international analytical instrument company, Waters Corporation, to launch a mass-market environmental toxin testing service for per- and polyfluoroalkyl substances (PFASs) in Taiwan. This service allows the general public to assess the environmental toxin risks and take timely countermeasures. More... (in Chinese) |
| PharmaEssentia's PV drug P1101 approved in UAE 1 November, 2023 PharmaEssentia announced that it had received marketing approval from the United Arab Emirates for Ropeginterferon alfa-2b (Ropeg, or P1101) for the treatment of Polycythemia Vera (PV) at an approved dose of 250 µg/0.5 mL. More... (in Chinese) |
| Merdury Biomedicals' 3D Printing Pharmaceutical Technology Granted US Patent Interview 1 November, 2023 Merdury Biomedicals (TW: 6932) announced that it had secured a US patent for its magnetic powder drug tablet printing technology. The patent is valid until March 18, 2042, and it plays a crucial role in the 3D powder printing process for supplying Active Pharmaceutical Ingredient (API) powders. With this patent, other companies are prohibited from manufacturing drugs using the same method, positioning Merdury Biomedicals as a leader in the 3D powder printing pharmaceutical industry. This technology has also received a new patent in Taiwan, and patent applications are currently under review in Taiwan, Australia, and mainland China. More... (in Chinese) |
| Researchers harness a combination of lab-grown cells to regenerate damaged heart muscle 31 October, 2023 Researchers at the University of Wisconsin–Madison and Academia Sinica of Taiwan have harnessed a combination of lab-grown cells to regenerate damaged heart muscle. The study, published in Circulation -; which addresses major challenges of using heart muscle cells, called cardiomyocytes, grown from stem cells -; takes a crucial step toward future clinical applications. More... |
| Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting 31 October, 2023 Foresee Pharmaceuticals (TPEx: 6576), announced today that the company will be presenting at the American Heart Association (AHA) 2023 Annual Meeting taking place in Philadelphia, PA, from November 11-13, 2023. The presentation will focus on Foresee’s first-in-class oral ALDH2 activator, FP-045, and the clinical design of Phase 2 pulmonary hypertension associated with interstitial lung disease (PH-ILD) clinical study (WINDWARD study) currently in planning. More... |
| PhytoHealth's Pain Relief New Drug Featured in International Journal 31 October, 2023 PhytoHealth (TW: 4108) is making inroads into the pain relief market. Recently the company announced that its oral pain relief medication, Oraphine, had completed collaborations with major Taiwanese medical institutions such as Tri-Service General Hospital, National Taiwan University Hospital, Tzu Chi Hospital, and Taipei Veterans General Hospital. These collaborations have confirmed the drug's pain-relief efficacy and safety. The research results have been accepted for publication in the internationally renowned medical journal The Clinical Journal of Pain. More... (in Chinese) |
| Taichung Veterans General Hospital unveils the GTP Laboratory 30 October, 2023 Cellular therapy and regenerative medicine are emerging medical technologies, for which Taichung Veterans General Hospital has unveiled the "Good Tissue Practice (GTP) Laboratory" to develop advanced cellular therapy. President Tsai inaugurated the lab and celebrated the 41st anniversary of the hospital on 28 October, expressing her willingness to contribute collectively to achieving medical excellence. More... |
| Easywell Biomedicals' Medication for Chronic Heart Failure Receives Approval in China 30 October, 2023 Easywell Biomedicals (TW: 1799) continues to achieve success with its new drug development efforts. The company's medication for treating chronic heart failure, HH-001 Sacubitril/Valsartan tablets, has received notification from China's National Medical Products Administration (NMPA) for drug certification. Easywell already has distribution partners in place and plans to commence shipments and contribute to revenue by the end of the first quarter next year. More... (in Chinese) |
| ============================== |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2024 (24-28 July, 2024) ============================== Taiwan Bio Industry Organization (TBIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ============================== |